Multiple candidates with unique anti-tumor features
Platform
Proven proof-of-concept: IDOV-Safe
First-in-human IV oncolytic virus delivery; currently testing different payloads
Built on our platform virus, IDOV-Safe has been safely intravenously delivered in humans, providing proof-of-concept of our technology. In addition to the novel safety switch feature embedded within IDOV-Safe, we have created three additional viruses, each with a proprietary anti-tumor payload. Ultimately, we intend to combine these feature sets into our flagship virus, IDOV-Immune, to create more potent platform-derived viruses.
IDOV-Safe™
First-ever “safety switch” to stop virus replication in healthy cells; Demonstrated improved efficacy against microsatellite stable colorectal cancer (MSS CRC) compared to standard of care.
IDOV-Immune™
Enhances anti-tumor immune responses, resulting in improved therapeutic efficacy.
IDOV-Stealth™
First-ever oncolytic virus that survives well in the bloodstream and resists clearance by NK and T-cell, allowing the virus to replicate in tumors longer.
IDOV-AntiAngio™
Prevents tumor blood vessel growth, cutting off the energy source of the tumor to further enhance the therapeutic effect of the oncolytic virus.
Clinical Pipeline
Our lead candidates are tailored for unique anti-tumor features
The IDOV virus targets all cancer types with unique feature sets targeting distinct tumor characteristics.
| Product | Pre-clinical | Phase I | Phase II | Phase III | Commercial |
|---|---|---|---|---|---|
|
IDOV-Safe
|
IIT / Ph I
|
||||
|
IDOV-Immune
|
Ph I
|
||||
|
IDOV-Immune+Stealth
|
Dev
|
||||
|
IDOV-Immune+AntiAngio
|
Dev
|